Boostrix tdap vaccine syringe 0.5ML
Ended Awarded Last action
- Contract number
- SPE2DR26FCS5J
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $22,338
Award facts
- Contract value 100% obligated
- $22,338.32 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $22,338.32 for Boostrix TDAP vaccine in 0.5mL syringes. This is a firm fixed-price, competitively awarded contract with no set-aside designation, with ultimate completion scheduled for December 4, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a maximum value of $999,999,999 and extends through December 2026, serving as a comprehensive global pharmaceutical support vehicle for military healthcare programs.
AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The company's extensive federal contract portfolio demonstrates capability across multiple therapeutic domains, including vaccines, specialty medications, and medical supplies. The Boostrix TDAP vaccine delivery supports DLA's medical supply chain and the Defense Health Agency's immunization requirements for military personnel and beneficiaries. AmerisourceBergen's competitive position in the federal marketplace reflects consistent performance in fulfilling open competition requirements, positioning the company as a key supplier within DLA's planned next-generation Pharmaceutical Prime Vendor Global Program strategy.
Quick answers
Who was awarded contract SPE2DR26FCS5J?
SPE2DR26FCS5J was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on December 3, 2025.
How much is contract SPE2DR26FCS5J worth?
The government has obligated $22,338 on SPE2DR26FCS5J.
Is contract SPE2DR26FCS5J an order under another contract?
Yes. SPE2DR26FCS5J is a delivery order under SPE2DR25D1100, an indefinite delivery contract.
Was contract SPE2DR26FCS5J competed?
The extent of competition for SPE2DR26FCS5J was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award